AstraZeneca financial docs confirm Japanese firm could buy Boulder plant
BOULDER — Last month the Colorado Economic Development Commission approved a series of tax incentives to help an unnamed company take over the vacant AstraZeneca PLC plant in Boulder. At the time, BizWest speculated that the unnamed firm was likely Japanese contract drug maker AGC Biologics. AstraZeneca confirmed those suspicions this week.
Buried nearly 200 pages into the firm’s recently released annual report is a direct reference to AGC and the Boulder plant at 5550 Airport Blvd.
The two firms “signed a letter of intent Nov. 27, 2019, to sell the facility to AGC Bio, with…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Boulder’s Human Relations Fund, which supports community-initiated activities that focus on civil rights, human rights…
-
Downtown Boulder’s Business Improvement District is recruiting two at-large board members.
-
Boulder City Council provided initial approval Thursday evening for a plan to raise the minimum…
-
The snowplow fleets in Boulder and Fort Collins have names selected from submissions by students…
